Enhancing the Management of Hypersomnia: Examining the Role of the Orexin System

Abstract

Excessive daytime sleepiness (EDS) is common. However, clinical features of excessive sleepiness can have broad and variable presentations. In addition, there can be an increased likelihood of medical or psychiatric comorbidity. Examination of the networks that regulate sleep–wake and circadian control reveals a complex and intricately designed integration system. Dysregulation in the coordination, effectiveness, or efficiency of these systems can contribute to developing EDS, and inform on the endotypes observed and pharmacologic considerations for treatment. The discovery and characterization of the diurnal expression and function of orexin (hypocretin) have led to a transformed understanding of sleep–wake control and EDS, as well as its role beyond sleep. As a result, a novel drug class, orexin agonists, is anticipated to emerge for clinical use in the near future. An understanding of orexin physiology and its transdisciplinary impact is necessary to best prepare for patient selection, use, and anticipated benefit and monitoring of both expected benefits and any other health change. This study provides a review of the range of clinical features and impact of EDS, the relationship between sleep–wake, circadian and other health networks, and an examination of orexin physiology with anticipatory guidance on the potential transdisciplinary role and impact of orexin agonists.

Keywords

narcolepsy - orexin - orexin agonists - sleepiness - cognition - hypersomnolence - idiopathic hypersomnia

Publication History

Accepted Manuscript online:
16 April 2025

Article published online:
12 May 2025

• References

• 1 Borbély AA. A two process model of sleep regulation. Hum Neurobiol 1982; 1 (03) 195-204
• 2 Shen J, Barbera J, Shapiro CM. Distinguishing sleepiness and fatigue: focus on definition and measurement. Sleep Med Rev 2006; 10 (01) 63-76
• 3 Ohayon MM. From wakefulness to excessive sleepiness: what we know and still need to know. Sleep Med Rev 2008; 12 (02) 129-141
• 4 Reichert CF, Deboer T, Landolt HP. Adenosine, caffeine, and sleep-wake regulation: state of the science and perspectives. J Sleep Res 2022; 31 (04) e13597
• 5 Borbély AA, Daan S, Wirz-Justice A, Deboer T. The two-process model of sleep regulation: a reappraisal. J Sleep Res 2016; 25 (02) 131-143
• 6 Verret L, Goutagny R, Fort P. et al. A role of melanin-concentrating hormone producing neurons in the central regulation of paradoxical sleep. BMC Neurosci 2003; 4: 19
• 7 Mieda M. The roles of orexins in sleep/wake regulation. Neurosci Res 2017; 118: 56-65
• 8 Yang Y, Park BY. Differences in structural connectome organization across sleep quality. Heliyon 2023; 9 (12) e23138
• 9 Ashbrook LH, Krystal AD, Fu YH, Ptáček LJ. Genetics of the human circadian clock and sleep homeostat. Neuropsychopharmacology 2020; 45 (01) 45-54
• 10 Smith RP, Easson C, Lyle SM. et al. Gut microbiome diversity is associated with sleep physiology in humans. PLoS One 2019; 14 (10) e0222394
• 11 Krueger JM. The role of cytokines in sleep regulation. Curr Pharm Des 2008; 14 (32) 3408-3416
• 12 Ohayon MM, Dauvilliers Y, Reynolds III CF. Operational definitions and algorithms for excessive sleepiness in the general population: implications for DSM-5 nosology. Arch Gen Psychiatry 2012; 69 (01) 71-79
• 13 Davidson RD, Blattner M, Scammell TE, Zhou ES. The impact of idiopathic hypersomnia on the social lives of young adults. Sleep Health 2025; 11 (01) 113-119
• 14 Davidson R, Biddle K, Scammell T, Nassan M, Zhou E. 498 it makes relationships harder: the role of narcolepsy in social and romantic relationships in young adults. Sleep (Basel) 2021; 44 (Suppl. 02) A196-A197
• 15 Davidson R, Blattner M, Scammell T, Zhou E. 0416 the impact of idiopathic hypersomnia on social and romantic relationships of young adults. Sleep (Basel) 2022; 45 (suppl 1): A186
• 16 O'Hare K, White N, Harding R. et al. Sluggish cognitive tempo and daytime sleepiness mediate relationships between sleep and academic performance. J Dev Behav Pediatr 2021; 42 (08) 637-647
• 17 Mullins HM, Cortina JM, Drake CL, Dalal RS. Sleepiness at work: a review and framework of how the physiology of sleepiness impacts the workplace. J Appl Psychol 2014; 99 (06) 1096-1112
• 18 Owens JA, Babcock D, Weiss M. Evaluation and treatment of children and adolescents with excessive daytime sleepiness. Clin Pediatr (Phila) 2020; 59 (4-5): 340-351
• 19 Melendres MC, Lutz JM, Rubin ED, Marcus CL. Daytime sleepiness and hyperactivity in children with suspected sleep-disordered breathing. Pediatrics 2004; 114 (03) 768-775
• 20 Tsai SY, Lin JW, Wu WW, Lee CN, Lee PL. Sleep disturbances and symptoms of depression and daytime sleepiness in pregnant women. Birth 2016; 43 (02) 176-183
• 21 Nordbakke S, Sagberg F. Sleepy at the wheel: knowledge, symptoms and behaviour among car drivers. Transp Res. Part F Traffic Psychol Behav 2007; 10 (01) 1-10
• 22 Perotta B, Arantes-Costa FM, Enns SC. et al. Sleepiness, sleep deprivation, quality of life, mental symptoms and perception of academic environment in medical students. BMC Med Educ 2021; 21 (01) 111
• 23 Kolla BP, He JP, Mansukhani MP, Frye MA, Merikangas K. Excessive sleepiness and associated symptoms in the U.S. adult population: prevalence, correlates, and comorbidity. Sleep Health 2020; 6 (01) 79-87
• 24 Wang L, Liu Q, Heizhati M, Yao X, Luo Q, Li N. Association between excessive daytime sleepiness and risk of cardiovascular disease and all-cause mortality: a systematic review and meta-analysis of longitudinal cohort studies. J Am Med Dir Assoc 2020; 21 (12) 1979-1985
• 25 Li J, Covassin N, Bock JM. et al. Excessive daytime sleepiness and cardiovascular mortality in US adults: a NHANES 2005–2008 follow-up study. Nat Sci Sleep 2021; 13: 1049-1059
• 26 Mallon L, Broman JE, Hetta J. Restless legs symptoms with sleepiness in relation to mortality: 20-year follow-up study of a middle-aged Swedish population. Psychiatry Clin Neurosci 2008; 62 (04) 457-463
• 27 Merlino G, Lorenzut S, Gigli GL. et al. Insomnia and daytime sleepiness predict 20-year mortality in older male adults: data from a population-based study. Sleep Med 2020; 73: 202-207
• 28 Covassin N, Lu D, St Louis EK. et al. Sex-specific associations between daytime sleepiness, chronic diseases and mortality in obstructive sleep apnea. Front Neurosci 2023; 17: 1210206
• 29 Wang YT, Hsu NW, Lin CH, Chen HC. Concurrence of insomnia and daytime sleepiness predicted 9-year mortality risk in community-dwelling older adults: the Yilan Study, Taiwan. J Gerontol A Biol Sci Med Sci 2023; 78 (12) 2371-2381
• 30 Piovezan RD, Jadczak AD, Tucker G, Visvanathan R. Daytime sleepiness predicts mortality in nursing home residents: findings from the frailty in residential aged care sector over time (FIRST) study. J Am Med Dir Assoc 2023; 24 (10) 1458-1464.e4
• 31 Chen HC, Hsu NW, Lin CH. Different dimensions of daytime sleepiness predicted mortality in older adults: Sex and muscle power-specific risk in Yilan Study, Taiwan. Sleep Med 2024; 113: 84-91
• 32 Li Y, Vgontzas AN, Fernandez-Mendoza J. et al. Objective, but not subjective, sleepiness is associated with inflammation in sleep apnea. Sleep 2017; 40 (02) zsw033
• 33 Kasai T, Taranto Montemurro L, Yumino D. et al. Inverse relationship of subjective daytime sleepiness to mortality in heart failure patients with sleep apnoea. ESC Heart Fail 2020; 7 (05) 2448-2454
• 34 Heybeli C, Soysal P, Oktan MA, Smith L, Çelik A, Kazancioglu R. Associations between nutritional factors and excessive daytime sleepiness in older patients with chronic kidney disease. Aging Clin Exp Res 2022; 34 (03) 573-581
• 35 Maghsoudi A, Azarian M, Sharafkhaneh A. et al. Age modulates the predictive value of self-reported sleepiness for all-cause mortality risk: insights from a comprehensive national database of veterans. J Clin Sleep Med 2024; 20 (11) 1785-1792
• 36 Frohnhofen H, Popp R, Frohnhofen K, Fulda S. Impact of daytime sleepiness on rehabilitation outcome in the elderly. Adv Exp Med Biol 2013; 755: 103-110
• 37 Slater G, Pengo MF, Kosky C, Steier J. Obesity as an independent predictor of subjective excessive daytime sleepiness. Respir Med 2013; 107 (02) 305-309
• 38 Bock J, Covassin N, Somers V. Excessive daytime sleepiness: an emerging marker of cardiovascular risk. Heart 2022; 108 (22) 1761-1766
• 39 Carvalho DZ, St Louis EK, Przybelski SA. et al. Sleepiness in cognitively unimpaired older adults is associated with CSF biomarkers of inflammation and axonal integrity. Front Aging Neurosci 2022; 14: 930315
• 40 Chen YC, Chen KD, Su MC. et al. Genome-wide gene expression array identifies novel genes related to disease severity and excessive daytime sleepiness in patients with obstructive sleep apnea. PLoS One 2017; 12 (05) e0176575
• 41 Amara AW, Chahine LM, Caspell-Garcia C. et al; Parkinson's Progression Markers Initiative. Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. J Neurol Neurosurg Psychiatry 2017; 88 (08) 653-662
• 42 Smagula SF, Jia Y, Chang CH, Cohen A, Ganguli M. Trajectories of daytime sleepiness and their associations with dementia incidence. J Sleep Res 2020; 29 (06) e12952
• 43 Van Eycken S, Neu D, Newell J, Kornreich C, Mairesse O. Sex-related differences in sleep-related PSG parameters and daytime complaints in a clinical population. Nat Sci Sleep 2020; 12: 161-171
• 44 Ng WL, Shaw JE, Peeters A. The relationship between excessive daytime sleepiness, disability, and mortality, and implications for life expectancy. Sleep Med 2018; 43: 83-89
• 45 Meyer C, Ferrari GJ, Barbosa DG, Andrade RD, Pelegrini A, Felden ÉPG. Analysis of daytime sleepiniess in adolescents by the pediatric daytime sleepiness scale: a systematic review. Rev Paul Pediatr 2017; 35 (03) 351-360
• 46 Joo S, Shin C, Kim J. et al. Prevalence and correlates of excessive daytime sleepiness in high school students in Korea. Psychiatry Clin Neurosci 2005; 59 (04) 433-440
• 47 van Litsenburg RRL, Waumans RC, van den Berg G, Gemke RJ. Sleep habits and sleep disturbances in Dutch children: a population-based study. Eur J Pediatr 2010; 169 (08) 1009-1015
• 48 Liu Y, Zhang J, Li SX. et al. Excessive daytime sleepiness among children and adolescents: prevalence, correlates, and pubertal effects. Sleep Med 2019; 53: 1-8
• 49 Owens JA, Spirito A, McGuinn M, Nobile C. Sleep habits and sleep disturbance in elementary school-aged children. J Dev Behav Pediatr 2000; 21 (01) 27-36
• 50 Stein MA, Mendelsohn J, Obermeyer WH, Amromin J, Benca R. Sleep and behavior problems in school-aged children. Pediatrics 2001; 107 (04) E60
• 51 Calhoun SL, Vgontzas AN, Fernandez-Mendoza J. et al. Prevalence and risk factors of excessive daytime sleepiness in a community sample of young children: the role of obesity, asthma, anxiety/depression, and sleep. Sleep 2011; 34 (04) 503-507
• 52 American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed, text revision. Darien, IL: American Academy of Sleep Medicine; 2023
• 53 Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001; 24 (12) 726-731
• 54 Eban-Rothschild A, Appelbaum L, de Lecea L. Neuronal mechanisms for sleep/wake regulation and modulatory drive. Neuropsychopharmacology 2018; 43 (05) 937-952
• 55 Stanyer EC, Hoffmann J, Holland PR. Orexins and primary headaches: an overview of the neurobiology and clinical impact. Expert Rev Neurother 2024; 24 (05) 487-496
• 56 Williams DL. Neural integration of satiation and food reward: role of GLP-1 and orexin pathways. Physiol Behav 2014; 136: 194-199
• 57 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin signaling: a complex, multifaceted process. Front Cell Neurosci 2022; 16: 812359
• 58 Karnani MM, Schöne C, Bracey EF. et al. Rapid sensory integration in orexin neurons governs probability of future movements. bioRxiv 2019; 620096
• 59 Schöne C, Burdakov D. Orexin/hypocretin and organizing principles for a diversity of wake-promoting neurons in the brain. Curr Top Behav Neurosci 2017; 33: 51-74
• 60 Pérez-Carbonell L, Mignot E, Leschziner G, Dauvilliers Y. Understanding and approaching excessive daytime sleepiness. Lancet 2022; 400 (10357): 1033-1046
• 61 Wang C, Wang Q, Ji B. et al. The orexin/receptor system: Molecular mechanism and therapeutic potential for neurological diseases. Front Mol Neurosci 2018; 11: 220
• 62 Sakurai T, Amemiya A, Ishii M. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92 (04) 573-585
• 63 de Lecea L, Kilduff TS, Peyron C. et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998; 95 (01) 322-327
• 64 Mieda M, Tsujino N, Sakurai T. Differential roles of orexin receptors in the regulation of sleep/wakefulness. Front Endocrinol (Lausanne) 2013; 4: 57
• 65 Moreira IS. Structural features of the G-protein/GPCR interactions. Biochim Biophys Acta 2014; 1840 (01) 16-33
• 66 Congreve M, de Graaf C, Swain NA, Tate CG. Impact of GPCR structures on drug discovery. Cell 2020; 181 (01) 81-91
• 67 Thompson MD, Sakurai T, Rainero I, Maj MC, Kukkonen JP. Orexin receptor multimerization versus functional interactions: Neuropharmacological implications for opioid and cannabinoid signalling and pharmacogenetics. Pharmaceuticals (Basel) 2017; 10 (04) 79
• 68 Azeez IA, Del Gallo F, Cristino L, Bentivoglio M. Daily fluctuation of orexin neuron activity and wiring: the challenge of “chronoconnectivity”. Front Pharmacol 2018; 9: 1061
• 69 Frank MG. Circadian regulation of synaptic plasticity. Biology (Basel) 2016; 5 (03) 31
• 70 Challet E. Keeping circadian time with hormones. Diabetes Obes Metab 2015; 17 (Suppl. 01) 76-83
• 71 Huang H, Acuna-Goycolea C, Li Y, Cheng HM, Obrietan K, van den Pol AN. Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal. J Neurosci 2007; 27 (18) 4870-4881
• 72 Voisin T, Rouet-Benzineb P, Reuter N, Laburthe M. Orexins and their receptors: structural aspects and role in peripheral tissues. Cell Mol Life Sci 2003; 60 (01) 72-87
• 73 Tsuneoka Y, Funato H. Whole brain mapping of orexin receptor mRNA expression visualized by branched in situ hybridization chain reaction. eNeuro 2024; 11 (02) ENEURO.0474 -23.2024
• 74 Prokofeva K, Saito YC, Niwa Y. et al. Structure and function of neuronal circuits linking ventrolateral preoptic nucleus and lateral hypothalamic area. J Neurosci 2023; 43 (22) 4075-4092
• 75 Grabauskas G, Moises HC. Gastrointestinal-projecting neurones in the dorsal motor nucleus of the vagus exhibit direct and viscerotopically organized sensitivity to orexin. J Physiol 2003; 549 (Pt 1): 37-56
• 76 Hopkins DA. Ultrastructure and synaptology of the nucleus ambiguus in the rat: the compact formation. J Comp Neurol 1995; 360 (04) 705-725
• 77 Hungs M, Mignot E. Hypocretin/orexin, sleep and narcolepsy. BioEssays 2001; 23 (05) 397-408
• 78 Hirtz C, Vialaret J, Gabelle A, Nowak N, Dauvilliers Y, Lehmann S. From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Sci Rep 2016; 6 (01) 25162
• 79 Jagota A. Priyanka, Bussa BR, Gunda V. Sleep and circadian rhythms as modulators of mental health in ageing. In: Brain and mental health in ageing. Berlin: Springer; 2024: 317-335
• 80 Barrile F, Cassano D, Fernandez G. et al. Ghrelin's orexigenic action in the lateral hypothalamic area involves indirect recruitment of orexin neurons and arcuate nucleus activation. Psychoneuroendocrinology 2023; 156: 106333
• 81 Laque A, Yu S, Qualls-Creekmore E. et al. Leptin modulates nutrient reward via inhibitory galanin action on orexin neurons. Mol Metab 2015; 4 (10) 706-717
• 82 Yamanaka A, Beuckmann CT, Willie JT. et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003; 38 (05) 701-713
• 83 Liguori C, Romigi A, Nuccetelli M. et al. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol 2014; 71 (12) 1498-1505
• 84 Feng Y, Liu T, Li XQ. et al. Neuroprotection by orexin-A via HIF-1α induction in a cellular model of Parkinson's disease. Neurosci Lett 2014; 579: 35-40
• 85 Imperatore R, Palomba L, Cristino L. Role of orexin-A in hypertension and obesity. Curr Hypertens Rep 2017; 19 (04) 34
• 86 Perez MV, Pavlovic A, Shang C. et al. Systems genomics identifies a key role for hypocretin/orexin receptor-2 in human heart failure. J Am Coll Cardiol 2015; 66 (22) 2522-2533
• 87 Yang LP. Suvorexant: first global approval. Drugs 2014; 74 (15) 1817-1822
• 88 Giliberto S, Shishodia R, Nastruz M. et al. A comprehensive review of novel FDA-approved psychiatric medications (2018–2022). Cureus 2024; 16 (03) e56561
• 89 Scott L. The pleasure principle: A critical examination of federal scheduling of controlled substances. Sw. UL Rev. 1999; 29: 447
• 90 James MH, Fragale JE, Aurora RN, Cooperman NA, Langleben DD, Aston-Jones G. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?. Neuropsychopharmacology 2020; 45 (05) 717-719
• 91 Huhn AS, Finan PH, Gamaldo CE. et al. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Sci Transl Med 2022; 14 (650) eabn8238
• 92 Gyawali U, James MH. Sleep disturbance in substance use disorders: the orexin (hypocretin) system as an emerging pharmacological target. Neuropsychopharmacology 2023; 48 (01) 228-229
• 93 Boof ML, Ufer M, Fietze I. et al. Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea. Sleep Med 2022; 92: 4-11
• 94 Born S, Gauvin DV, Mukherjee S, Briscoe R. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regul Toxicol Pharmacol 2017; 86: 181-192
• 95 Garcia-Borreguero D, Aragón AG, Moncada B. et al. Treatment of sleep, motor and sensory symptoms with the orexin antagonist suvorexant in adults with idiopathic restless legs syndrome: A randomized double-blind crossover proof-of-concept study. CNS Drugs 2024; 38 (01) 45-54
• 96 Recourt K, de Boer P, Zuiker R. et al. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl Psychiatry 2019; 9 (01) 216
• 97 Dauvilliers Y, Mignot E, Del Río Villegas R. et al. Oral orexin receptor 2 agonist in narcolepsy type 1. N Engl J Med 2023; 389 (04) 309-321
• 98 Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15 (04) 241-243
• 99 Takeda Pharmaceuticals. Takeda pharmaceutical company 43rd annual J.P. morgan healthcare conference. Accessed February 27, 2025 at: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/ https://assets-dam.takeda.com/image/upload/Global/Investor/events/2025/documents/JPMHC_2025_presentation.pdf
• 100 Takeda Pharmaceuticals. A study of TAK-360 in adults with idiopathic hypersomnia. Accessed February 2, 2025 at: https://clinicaltrials.gov/study/NCT06812078?intr=tak-360&rank=1
• 101 Alkermes. Alkermes 2025. Accessed February 27, 2025 at: https://chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://investor.alkermes.com/static-files/a779844f-db8b-4859-8dac-775d11142f8f
• 102 Yee B, Chapman J, Grunstein R. et al. O013 preliminary results from a phase 1 study of ALKS 2680, an orexin-2 receptor agonist, in healthy participants and patients with narcolepsy or idiopathic hypersomnia. Sleep Adv 2023; 4 (Suppl. 01) A5-A6
• 103 Centessa pharmaceuticals. Accessed February 27, 2025 at: https://chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://investors.centessa.com/static-files/04030d63-c59d-488d-862e-9f9b2158a35e
• 104 Eisai Pharmaceuticals. A study to evaluate the efficacy, safety, and tolerability of E2086 compared to placebo and active comparator in adult participants with narcolepsy type 1. Accessed February 27, 2025 at: https://clinicaltrials.gov/study/NCT06462404?cond=E2086&rank=3
• 105 Hatanaka K, Suzuki H, Michikawa F. et al A novel orally-available selective orexin 2 receptor agonist, E2086, enhances wake-promotion and treats narcolepsy-like symptoms in narcolepsy model mice. Neuropsychopharmacology 2022; 47: S401-S402
• 106 Takeda Pharmaceuticals. A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-925 in healthy volunteers and participants with narcolepsy. Accessed February 25, 2020 at: https://clinicaltrials.gov/study/NCT03748979?intr=tak-925&rank=4
• 107 Takeda Pharmaceuticals. A study of a single intravenous infusion dose of TAK-925 in participants with idiopathic hypersomnia. Accessed February 25, 2023 at: https://clinicaltrials.gov/study/NCT04091438?intr=tak-925&rank=1
• 108 Takeda Pharmaceuticals. A study of danavorexton in people with obstructive sleep apnea after general anesthesia for abdominal surgery. Accessed February 25, 2024 at: https://clinicaltrials.gov/search?intr=tak-925